Although PLK1 inhibitors combined with paclitaxel or PARPi have synergistic effects in inhibiting tumor cell growth in preclinical models of EOC, there are currently no reports on the combination of PLK1 inhibitors with other chemotherapeutic drugs in clinical trials of EOC. Here, PLK1 is linked to neoplasm.